CTOR Citius Oncology
Citius Oncology earnings company data as of 7:18 PM ET 8/21
- 0 of 1 EPS beats
History
1 period, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 14 Aug | EPS | -0.07 | -0.08 | Miss |
| Rev | — | $1.5M | — |
Insider trades
Open-market buys and sales by CTOR's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- None no planned (10b5-1) sales
No open-market buys or sales on file.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 8.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| DEF 14A | DEFINITIVE PROXY STATEMENT | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | QUARTERLY REPORT | Filing Doc | |
| 424B3 | PROSPECTUS | Filing Doc | |
| 8-K | 5.02,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 424B3 | PROSPECTUS SUPPLEMENT | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 424B3 | Filing Doc | ||
| 424B3 | PROSPECTUS SUPPLEMENT | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | QUARTERLY REPORT | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 1.01,2.03,3.02,8.01,9.01 | Filing Doc | |
| 424B3 | PROSPECTUS SUPPLEMENT | Filing Doc | |
| 424B3 | PROSPECTUS SUPPLEMENT | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 3.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.